Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicine
Many current clinical therapies for chronic diseases involve administration of drugs using dosage and bioavailability parameters estimated for a generalized population. This standard approach carries the risk of under dosing, which may result in ineffective treatment, or overdosing, which may cause...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2022.986210/full |
| _version_ | 1798001357232275456 |
|---|---|
| author | Bozhidar-Adrian Stefanov Martin Fussenegger Martin Fussenegger |
| author_facet | Bozhidar-Adrian Stefanov Martin Fussenegger Martin Fussenegger |
| author_sort | Bozhidar-Adrian Stefanov |
| collection | DOAJ |
| description | Many current clinical therapies for chronic diseases involve administration of drugs using dosage and bioavailability parameters estimated for a generalized population. This standard approach carries the risk of under dosing, which may result in ineffective treatment, or overdosing, which may cause undesirable side effects. Consequently, maintaining a drug concentration in the therapeutic window often requires frequent monitoring, adversely affecting the patient’s quality of life. In contrast, endogenous biosystems have evolved finely tuned feedback control loops that govern the physiological functions of the body based on multiple input parameters. To provide personalized treatment for chronic diseases, therefore, we require synthetic systems that can similarly generate a calibrated therapeutic response. Such engineered autonomous closed-loop devices should incorporate a sensor that actively tracks and evaluates the disease severity based on one or more biomarkers, as well as components that utilize these molecular inputs to bio compute and deliver the appropriate level of therapeutic output. Here, we review recent advances in applications of the closed-loop design principle in biomedical implants for treating severe and chronic diseases, highlighting translational studies of cellular therapies. We describe the engineering principles and components of closed-loop therapeutic devices, and discuss their potential to become a key pillar of personalized medicine. |
| first_indexed | 2024-04-11T11:34:46Z |
| format | Article |
| id | doaj.art-88be0ef570054906b50a5db6214e3519 |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-04-11T11:34:46Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-88be0ef570054906b50a5db6214e35192022-12-22T04:26:01ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852022-09-011010.3389/fbioe.2022.986210986210Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicineBozhidar-Adrian Stefanov0Martin Fussenegger1Martin Fussenegger2ETH Zürich, Department of Biosystems Science and Engineering, Basel, SwitzerlandETH Zürich, Department of Biosystems Science and Engineering, Basel, SwitzerlandFaculty of Life Science, University of Basel, Basel, SwitzerlandMany current clinical therapies for chronic diseases involve administration of drugs using dosage and bioavailability parameters estimated for a generalized population. This standard approach carries the risk of under dosing, which may result in ineffective treatment, or overdosing, which may cause undesirable side effects. Consequently, maintaining a drug concentration in the therapeutic window often requires frequent monitoring, adversely affecting the patient’s quality of life. In contrast, endogenous biosystems have evolved finely tuned feedback control loops that govern the physiological functions of the body based on multiple input parameters. To provide personalized treatment for chronic diseases, therefore, we require synthetic systems that can similarly generate a calibrated therapeutic response. Such engineered autonomous closed-loop devices should incorporate a sensor that actively tracks and evaluates the disease severity based on one or more biomarkers, as well as components that utilize these molecular inputs to bio compute and deliver the appropriate level of therapeutic output. Here, we review recent advances in applications of the closed-loop design principle in biomedical implants for treating severe and chronic diseases, highlighting translational studies of cellular therapies. We describe the engineering principles and components of closed-loop therapeutic devices, and discuss their potential to become a key pillar of personalized medicine.https://www.frontiersin.org/articles/10.3389/fbioe.2022.986210/fullsynthetic biologygene switchesgene regulation and expressioncell-based therapiespersonalised medicine |
| spellingShingle | Bozhidar-Adrian Stefanov Martin Fussenegger Martin Fussenegger Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicine Frontiers in Bioengineering and Biotechnology synthetic biology gene switches gene regulation and expression cell-based therapies personalised medicine |
| title | Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicine |
| title_full | Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicine |
| title_fullStr | Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicine |
| title_full_unstemmed | Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicine |
| title_short | Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicine |
| title_sort | biomarker driven feedback control of synthetic biology systems for next generation personalized medicine |
| topic | synthetic biology gene switches gene regulation and expression cell-based therapies personalised medicine |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2022.986210/full |
| work_keys_str_mv | AT bozhidaradrianstefanov biomarkerdrivenfeedbackcontrolofsyntheticbiologysystemsfornextgenerationpersonalizedmedicine AT martinfussenegger biomarkerdrivenfeedbackcontrolofsyntheticbiologysystemsfornextgenerationpersonalizedmedicine AT martinfussenegger biomarkerdrivenfeedbackcontrolofsyntheticbiologysystemsfornextgenerationpersonalizedmedicine |